BioCryst Pharma (BCRX) Continues Higher Following Speculation of Ebola Cure

BioCryst (Nasdaq: BCRX) is taking another leg higher today following positive commentary in Forbes.

Specifically, Forbes refers to BioCryst's BCX4430, which could be a cure for the Ebola virus. The author stated, The new drug, BCX4430, works by blocking the reproduction of the virus inside infected cells ... Chemically, it is similar to adenosine, one of the four letters of the genetic code ... But when the virus tries to build new copies of itself using BCX4430 instead of adenosine, the process comes to a grinding halt.

Read the rest of the piece here. Shares of BioCryst are up 7.9 percent.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• European stocks mixed; Euro banking sector, Meta Platforms in the spotlight
• BioCryst to Report First Quarter 2024 Financial Results on May 6